Bicycle Therapeutics

Abbvie hopes to turn around the fortunes of Sting

Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.

Asco 2019 – Seattle sees an Adcetris follow-up on the horizon at last

A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.

February 08, 2019

Upcoming events – cancer readouts for Merck & Co and Seattle

Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.

October 11, 2017

Kalvista leads the kallikrein eye disease pipeline

August 31, 2017

Corporate venture firms – dedicated followers of fashion?

Eagerly pursuing all the latest fads and trends.

June 15, 2017

Interview – Bicycle takes a spin into the clinic

December 02, 2016

Snippet roundup: Deals for Boston and Astra, data for Novo and an approval for Biosurfit

July 16, 2015

Record raise sees Immunocore square up to its peers

September 15, 2011

EP Vantage Interview – Noxxon's transformation entering pivotal phase

October 14, 2009

Vantage Point – Corporate VCs plugging the gap